The combination of Semaminone and osimertinib demonstrated a synergistic growth inhibition in hepatocellular carcinoma (HCC) 827-osi resistant cells, suggesting a potential salvage therapy for EGFR mutation-mediated osimertinib resistance in NSCLC. The gene discussed is EGFR; the disease is hepatocellular carcinoma.